Fundacion MEDINA presents in Boston m3DinAI, a New Anti-Tumor Drug Screening Platform
June 18, 2025
Rosario Fernández Godino, Head of the Screening and Target Validation Area, has presented an innovative platform for anti-tumor drug screening at the BIO International Convention in Boston. This tool, developed entirely in Granada, promises to accelerate the search for cancer treatments.
The m3DinAI platform combines artificial intelligence with 3D tumor models, known as spheroids. These models mimic the real tumor environment much more precisely, allowing for more reliable testing of drug effectiveness. The most notable feature of m3DinAI is its ability to automatically analyse and quantify changes in these tumor cells after treatment with different compounds. This not only speeds up the process of identifying potential anti-tumor drugs but also minimises human error and subjectivity.
The presentation of this technology at one of the world’s most important biotechnology forums demonstrates how Fundacion MEDINA is transforming the future of drug discovery.
